SB656933 ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
299	嚢胞性線維症	2

299. 嚢胞性線維症

---

臨床試験数 : 1,695 /  薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00903201 (ClinicalTrials.gov)	September 28, 2009	14/5/2009	28 Day Repeat Dose in Cystic Fibrosis Patients	A Randomized, Double Blind, Parallel Group, Placebo Controlled 28 Day Study to Investigate the Safety, Tolerability and Pharmacodynamics of SB-656933 in Patients With Cystic Fibrosis.	Cystic Fibrosis	Drug: SB656933;Drug: Placebo	GlaxoSmithKline	NULL	Completed	18 Years	N/A	All	146	Phase 2	United States;Canada;France;Germany;Israel
2	NCT00605761 (ClinicalTrials.gov)	February 2008	18/1/2008	SD Cystic Fibrosis Study	An Open Label Dose Ascending, Single Dose Study to Investigate the Pharmacokinetics of SB-656933 in Subjects With Cystic Fibrosis.	Cystic Fibrosis	Drug: SB656933	GlaxoSmithKline	NULL	Completed	16 Years	N/A	Both	9	Phase 1	United States